Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | Plasma biomarkers for population-based Alzheimer’s disease screening

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, discusses details from a study evaluating Alzheimer’s disease (AD) plasma biomarkers for identifying at-risk groups in a real-world, population-based cohort. The study revealed that abnormal plasma Aβ42/40 ratio identified older adult groups with lower memory scores, higher dementia risks, and higher ADRD biomarker levels, including NfL, GFAP, and p-tau181.These results hold promise for population screening, showing that a simple non-invasive test can unveil abnormalities indicative of AD. The cost-effectiveness and convenience of plasma biomarkers also position them as valuable pre-screening tools before more invasive/costly tests like cerebrospinal fluid (CSF) biomarkers or PET scans. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.